Bristol-Myers Squibb (BMY) versus Its Peers Critical Survey
Bristol-Myers Squibb (NYSE: BMY) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Bristol-Myers Squibb to related businesses based on the strength of its analyst recommendations, dividends, profitability, institutional ownership, risk, valuation and earnings.
This table compares Bristol-Myers Squibb and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Bristol-Myers Squibb Competitors||-2,845.49%||-66.88%||-8.71%|
This is a breakdown of current ratings and target prices for Bristol-Myers Squibb and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Bristol-Myers Squibb Competitors||827||3703||6739||182||2.55|
Bristol-Myers Squibb presently has a consensus target price of $62.85, indicating a potential downside of 2.44%. As a group, “Pharmaceuticals” companies have a potential upside of 23.49%. Given Bristol-Myers Squibb’s peers stronger consensus rating and higher probable upside, analysts plainly believe Bristol-Myers Squibb has less favorable growth aspects than its peers.
Insider & Institutional Ownership
68.8% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.2% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Bristol-Myers Squibb has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb’s peers have a beta of 0.90, suggesting that their average stock price is 10% less volatile than the S&P 500.
Valuation and Earnings
This table compares Bristol-Myers Squibb and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Bristol-Myers Squibb||$20.24 billion||$6.01 billion||23.43|
|Bristol-Myers Squibb Competitors||$8.20 billion||$2.68 billion||-1.31|
Bristol-Myers Squibb has higher revenue and earnings than its peers. Bristol-Myers Squibb is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Bristol-Myers Squibb pays an annual dividend of $1.56 per share and has a dividend yield of 2.4%. Bristol-Myers Squibb pays out 56.7% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.4% and pay out 69.9% of their earnings in the form of a dividend. Bristol-Myers Squibb has increased its dividend for 7 consecutive years. Bristol-Myers Squibb is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.
Bristol-Myers Squibb beats its peers on 10 of the 15 factors compared.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company’s products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.